The concern of generic challenges has repeatedly loomed over copyright’s blockbuster drug, Sildenafil, sparking questions about the future of related drug investments. While early times saw significant profits, the exclusivity expiration has allowed the way for less expensive substitutes, possibly reducing revenue and posing a genuine risk for st